Extended Follow-up of Patients with Melanoma Treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517729-20-00

Acronym

R3767-ONC-2466

Enrollment

Registered

2025-07-04

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Brief summary

Death from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613

Detailed description

Progressive-Free Survival (PFS), Objective Response Rate (ORR), Duration of Response (DOR), Disease Control Rate (DCR), Incidence of Serious Adverse Events (SAEs), Severity of SAEs, Incidence of treatment-related AEs, Severity of treatment-related AEs, Incidence of anti-cancer therapies received since end of treatment with fianlimab and cemiplimab in study R3767-ONC-1613

Interventions

DRUGLIBTAYO 350 mg concentrate for solution for infusion.

DRUGFianlimab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Death from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613	—

Secondary

Measure	Time frame
Progressive-Free Survival (PFS), Objective Response Rate (ORR), Duration of Response (DOR), Disease Control Rate (DCR), Incidence of Serious Adverse Events (SAEs), Severity of SAEs, Incidence of treatment-related AEs, Severity of treatment-related AEs, Incidence of anti-cancer therapies received since end of treatment with fianlimab and cemiplimab in study R3767-ONC-1613	—

Countries

Ireland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026